Researchers continue to seek effective treatments for platinum-resistant ovarian cancer. At a recent medical conference, Tao Zhu from Zhejiang Cancer Hospital presented…
Browsing: AACR
Recent clinical data presents alisertib (also known as elisrasib) as a highly potent treatment option for patients with KRAS G12C-mutant…
The management of KRAS G12D-mutant non-small cell lung cancer (NSCLC) has challenged clinicians for years. Doctors long relied on standard…
RAS Inhibitor Resistance in PDAC at AACR 2025 At the AACR 2025 Annual Meeting in Chicago, Dr. Andrew Aguirre from…
A New Approach to MMRd/MSI-H Tumors At the AACR Annual Meeting 2025 in Chicago, Dr. Andrea Cercek presented compelling data…
Published on May 3, 2025 Antibody-drug conjugates (ADCs) have revolutionized oncology, offering targeted cancer treatments that minimize harm to healthy…
Introduction Zongertinib (BI 1810631) has shown promising results in treating HER2-mutant non-small cell lung cancer (NSCLC), with a 71% response…
Introduction The KEYNOTE-689 clinical trial has provided a significant update on pembrolizumab’s role in treating resectable locally advanced head and…
Date: March 11, 2025 Renowned Cancer Researcher Honored in 2025 The American Association for Cancer Research (AACR) and the Pezcoller…
LOS ANGELES AACR IO 2025 At a recent oncology session from AACR Immunotherapy 2025, Melissa G. Lechner, MD, PhD, presented…
Posted on February 28, 2025 | Jose Ramon Conejo-Garcia,MD, PHD – Duke Cancer Institute Cancer immunotherapy has long been dominated…
February 26, 2025 | By Michael Karin, Phd Liver cancer, specifically hepatocellular carcinoma (HCC), is on the rise—and a sneaky…
Los Angeles, February 2025 The AACR IO 2025 conference in Los Angeles has become a beacon for cutting-edge cancer research.…
Los Angeles, February 2025 – The inaugural AACR IO Conference kicked off with an electrifying start, bringing together the world’s…